네프로스(NEPH) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

NEPH

Nephros Inc

7월 28일 9:44 AM ET (한국 7/28 22:44)

$3.43

-0.21 ▼ -5.77%

네프로스(NEPH) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$37M

스몰캡

P/E

48.5

적정 수준

배당수익률

없음

52주 위치

20%

저점 +29% · 고점 -47%

애널리스트

매수

Fundamental health

vs. Medical Instruments & Supplies

수익성

Top 10%

성장

Top 35%

밸류에이션

Top 39%

재무 안정

Top 45%

💰 Is this stock pricier than usual right now?

Compared to this company's own recent 2년 (not other companies).

Very cheap

Cheap

Typical

Pricey

Very pricey

Simply put — what you pay today to own $1 of this company's yearly earnings is 48원. Over the past 2년, it usually traded around 39원. On the pricier side versus its own history.

Pricy doesn't mean bad — it means expectations are already baked in.· based on 1.6 profitable years

Index ⓘ	-	P/E ⓘ	48.51	EPS (ttm) ⓘ	0.07	Insider Own ⓘ	13.37%	Shs Outstand ⓘ	10.8M	Perf Week ⓘ	-6.79%
Market Cap ⓘ	0.04B	Forward P/E ⓘ	23.66	EPS next Y ⓘ	262.5%	Insider Trans ⓘ	-	Shs Float ⓘ	9.4M	Perf Month ⓘ	4.89%
Enterprise Value ⓘ	0.03B	PEG ⓘ	-	EPS next Q ⓘ	0.02	Inst Own ⓘ	48.92%	Short Float ⓘ	0.33%	Perf Quarter ⓘ	19.51%
Income ⓘ	0.00B	P/S ⓘ	1.95	EPS this Y ⓘ	-63.64%	Inst Trans ⓘ	-0.79%	Short Ratio ⓘ	1.63	Perf Half Y ⓘ	-26.71%
Sales ⓘ	0.02B	P/B ⓘ	3.48	EPS next 5Y ⓘ	-	ROA ⓘ	6.07%	Short Interest ⓘ	0.03M	Perf YTD ⓘ	-29.71%
Book/sh ⓘ	0.99	P/C ⓘ	9.26	EPS past 3/5Y ⓘ	-	ROE ⓘ	7.76%	52W High ⓘ	-46.57% ($6.42)	Perf Year ⓘ	-3.92%
Cash/sh ⓘ	0.37	P/FCF ⓘ	22.57	Sales past 3/5Y ⓘ	23.5% 17.02%	ROIC ⓘ	6.89%	52W Low ⓘ	28.81% ($2.66)	Perf 3Y ⓘ	152.21%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	42.21	EPS Y/Y TTM ⓘ	-3.31%	Gross Margin ⓘ	59.27%	Volatility(W/M) ⓘ	7.24% 7.52%	Perf 5Y ⓘ	-62.72%
Dividend TTM ⓘ	-	EV/Sales ⓘ	1.79	Sales Y/Y TTM ⓘ	23.25%	Oper. Margin ⓘ	3.54%	ATR (14) ⓘ	0.25	Perf 10Y ⓘ	41.15%
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	3.12	EPS Q/Q ⓘ	-75.86%	Profit Margin ⓘ	4.06%	RSI (14) ⓘ	46.06	Recom ⓘ	1.67
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	4.55	Sales Q/Q ⓘ	6.87%	SMA20 ⓘ	-3.92% ($3.57)	Beta ⓘ	1.51	Target Price ⓘ	$6
Payout ⓘ	-	Debt/Eq ⓘ	0.09	Earnings ⓘ	2026/7/22	SMA50 ⓘ	-1.75% ($3.49)	Rel Volume ⓘ	0.42	Prev Close ⓘ	$3.64
Employees ⓘ	36	LT Debt/Eq ⓘ	0.05	EPS/Sales Surpr. ⓘ	-	SMA200 ⓘ	-15.43% ($4.06)	Avg Volume(3M) ⓘ	0.02M	Price ⓘ	$3.43
IPO ⓘ	2004/9/21	Option/Short ⓘ	No/Yes			Trades ⓘ	106	Volume ⓘ	7,996	Change ⓘ	-5.77%

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

26.3

Revenue Net income 최근 분기: 매출 $5M (YoY +7%) · 순이익 $0M (YoY -75%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Nephros Inc (NEPH) Investment Analysis

What kind of company is Nephros Inc?

네프로스(NEPH)

Healthcare · Medical Instruments & Supplies

Small-Cap — Low Volume, High Volatility

💧 Nephros() is a U.S.-based water treatment and medical filter specialist headquartered in New Jersey. The company supplies ultrafine filters built on hollow-fiber membrane technology to hospitals, dialysis centers, and commercial facilities. Its product range covers infection control, dialysis water purification, commercial drinking water, and PFAS (forever chemicals) removal, and it is a small profitable company that has posted four consecutive quarters in the black.

Learn more about Nephros Inc →

Market Cap

$0.0B

Approx. KRW 0.1 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank5058

Employees36people

IPO2004/09/21

Current Price$3.43 ≈ 4,699원

NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 7월 22일 (수) · 장 시작 전 EPS +0.0% 매출 +0.0%

🔔 Earnings release 2026년 5월 7일 (목) · 장 마감 후 EPS +0.0% 매출 +3.9%

🔔 Earnings release 2026년 3월 12일 (목) · 장 마감 후 EPS +0.0% 매출 +6.3%

Is it profitable?

Solid company — profitability & finances both healthy

Strong earnings and excellent financial health

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

3.5%

✓ 우수

My positionTop 25%

Low range Average High range

Medical Instruments & Supplies 초소형주 Median -41.1% · Top 25%

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

4.1%

✓ 우수

My positionTop 25%

Low range Average High range

Medical Instruments & Supplies 초소형주 Median -29.9% · Top 23%

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

59.3%

✓ 우수

My positionTop 25%

Low range Average High range

Medical Instruments & Supplies 초소형주 Median 37.8% · Top 16%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

7.8%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 초소형주 Median -98.0% · Top tier

💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)

ROA

Annual earnings relative to total company assets

6.1%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 초소형주 Median -59.3% · Top tier

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

6.9%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 초소형주 Median -77.3% · Top tier

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.09

✓ Very low debt

My positionTop 25%

Low range Average High range

Medical Instruments & Supplies Median 0.26

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

4.55

✓ 양호

My positionMid-range

Low range Average High range

Medical Instruments & Supplies Median 2.34

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

3.12

✓ 양호

My positionMid-range

Low range Average High range

Medical Instruments & Supplies Median 1.97

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook

Price targets, growth, and valuation are favorable

애널리스트 목표가

$6.00

현재가 대비 +74.9%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

23.66배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

내년 EPS 예상 성장률

+262.5%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance

Generally in line with estimates

예상 상회

예상 부합

예상 하회

상회 비율

+0.0%

평균 서프라이즈

2026.07.22

부합

+0.0%

2026.05.07

부합

실적 $0.01 · 예상 $0.01 +0.0%

2026.03.12

부합

실적 $0.01 · 예상 $0.01 +0.0%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth

Mid-range within the industry

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

-63.6%

부진

My positionBottom 25%

Low range Average High range

미분류 초소형주 Median 29.4% · Bottom 15%

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+262.5%

우수

My positionTop 5%

Low range Average High range

미분류 초소형주 Median 40.2% · Top tier

📊 How much has it grown? (actual results)

Past 5-Year Revenue

How much revenue grew over the past 5 years

+17.0%

우수

My positionTop 25%

Low range Average High range

미분류 초소형주 Median 2.8% · Top 14%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+6.9%

양호

My positionMid-range

Low range Average High range

미분류 초소형주 Median -2.6% · Top 40%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -131%p below the market

NEPH -62.7% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-131.1%p

Significantly behind the market

vs Health Care (XLV)

-87.2%p

Significantly behind the sector average

1-year basis

vs S&P 500

-19.9%p

behind the market

vs Health Care (XLV)

-23.6%p

behind the sector average

Rank among peers

5-year return Upper-Mid (43%) Based on 18 peers

1-year return Upper-Mid (30%) Based on 23 peers

Current position within 52-week range

Low (-28.8%p) High (-46.6%p)

Current price is 28.8% above the 52-week low and 46.6% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-32.4%

Annualized volatility

79.1%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴

Current diagnosis · 2026-07-27

Downtrend zone

Current price $3.43 below the midline ($3.59). Normal downward flow. Inside the Ichimoku cloud (neutral).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

⚡

Current diagnosis · 2026-07-27

Death cross — bearish reversal signal

MACD(0.053) crossed below Signal(0.066). Trend reversal possible; read as a sell entry point.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴

Current diagnosis · 2026-07-27

Bearish zone

RSI 45.8 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 26.3.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average

Cheap on Vs. Sales, In line with peers on Vs. Earnings·Vs. Assets·Vs. Cash Flow

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Mid-range

🏢 Vs. Assets Mid-range

🧾 Vs. Sales Cheap

💧 Vs. Cash Flow Mid-range

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

48.51x

✓ Fair

My positionMid-range

Low range Average High range

Medical Instruments & Supplies median 35.22x · Around the industry average

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

23.66x

✓ Fair

My positionMid-range

Low range Average High range

Medical Instruments & Supplies median 18.44x · Around the industry average

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

3.48x

✓ Fair

My positionMid-range

Low range Average High range

Medical Instruments & Supplies 초소형주 median 1.95x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

1.95x

✓ Cheap

My positionMid-range

Low range Average High range

Medical Instruments & Supplies 초소형주 median 2.38x · Around the industry average

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

42.21x

✓ Pricey

My positionBottom 25%

Low range Average High range

Medical Instruments & Supplies median 14.76x · Bottom 13% — expensive within the industry

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

22.57x

✓ Cheap

My positionMid-range

Low range Average High range

Medical Instruments & Supplies median 25.16x · Around the industry average

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$6.00 vs. current price +74.9%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Medical Instruments & Supplies

Who owns it?

Ownership is broadly stable

Institutional modest net selling -0.8% · Short interest light 0.3%

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

0.0%

Insiders little change

🏦 Institutions (funds & investors)

-0.8%

Institutions net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 48.9%

Moderate institutional participation

Healthcare 초소형주 Median 14.2%

🧑‍💼 Insiders 13.4%

Founder/management large holders (strong skin-in-the-game)

Healthcare 초소형주 Median 16.1%

👤 Retail investors (estimated) 37.7%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

0.3%

Low — limited short-side pressure

Healthcare 초소형주 Median 3.9%

Past 90 days Little change

Short interest days to cover

1.6 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 10.8M주

Float (tradable shares) 9.4M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding NEPH

ETFs with the highest weightings · 5 total shown

DCOR

Dimensional US Core Equity 1 ETF

0.00%

$3.3B

DFAC

Dimensional U.S. Core Equity 2 ETF

0.00%

$47.5B

DFSU

Dimensional US Sustainability Core 1 ETF

0.00%

$2.2B

VTI

Vanguard Total Stock Market ETF

0.00%

$657.4B

VXF

Vanguard Extended Market Index ETF

0.00%

$30.4B

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
NEPH This Stock	$37.2M	48.5 ▼	3.5 ▼	7.76% ▲	-	-5.8%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 네프로스(NEPH)?

네프로스(NEPH) belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.

What is the market cap of NEPH?

The market cap of NEPH is approximately $37M, ranking 5,058 within its sector.

What is the P/E ratio of NEPH?

NEPH has a P/E ratio of approximately 48.5x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for NEPH?

NEPH has recorded a 52-week high of $6.42 and a low of $2.66.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.